Navigation Links
In Battle Against Healthcare Associated Infections: Continuing Research on Friendly Bacteria
Date:5/4/2011

CLEVELAND, May 4, 2011 /PRNewswire/ -- Ganeden Biotech announced today that the company will present new in vivo data on the effect of its GanedenBC30 probiotic strain in C. diff infection at the Digestive Disease Week (DDW) conference in Chicago, Ill., from May 7-10, 2011. Jointly with its collaborator, Dr. Leo R. Fitzpatrick, Associate Professor from the Department of Pharmacology, Penn State College of Medicine, Pa., Ganeden will present data on the effect of GanedenBC30 on impacting C. diff-induced colitis in mice. Following an established protocol for colitis induced by C. diff, GanedenBC30 demonstrated a significant effect on improving stool consistency and also improved animal survival and other indices of colonic inflammation.

(Logo: http://photos.prnewswire.com/prnh/20041213/CLM031LOGO)

Clostridium difficile (C. diff) is a species of gram-positive bacteria that causes severe diarrhea and other intestinal disease when competing, friendly bacteria in the gut flora are wiped out by antibiotics.  C. diff infection typically occurs in hospital or healthcare settings after antibiotic administration.  The U.S. Agency for Healthcare Research and Quality (AHRQ) estimates that C. diff infections occur in 10 of every 1,000 hospitalizations.  AHRQ research found that patients with C. diff were hospitalized almost three times longer than uninfected patients and that the in-hospital death rate for patients with C. diff was almost five times the overall rate.

Treatment for C. diff infection is generally focused on administering antibiotics to kill the C. diff bacteria once an infection is diagnosed.  Currently, there is one FDA-approved antibiotic for C. diff, vancomycin.  However, because C. diff infection first arises when the body's own protective ecosystem of friendly bacteria is destroyed by antibiotics, there is a risk for re-infection following antibiotic treatment for C. diff. Patients can get caught in a vicious cycle of infection, treatment, and re-infection.  Many researchers are interested in trying to rebuild that ecosystem as soon as antibiotics are administered in the first place.

"There is a tremendous need for new therapies for C. diff infection, and we are encouraged that this new research supports our in vitro data showing the potential of our GanedenBC30 probiotic strain to help," said Marshall Fong, vice president of marketing for Ganeden. "We hope to continue the research on GanedenBC30 in a hospital setting to gauge the real-life impact of GanedenBC30 in preventing or reducing the severity of C. diff infections."

About Ganeden Biotech 

Ganeden Biotech Inc. is a Cleveland, Ohio, based company and the largest seller of over-the-counter probiotics in U.S. food, drug, and mass market retailers with its Digestive Advantage and Sustenex brands.  It also licenses its patented strain of probiotic bacteria, GanedenBC30, as an ingredient for use in commercial food and beverage applications.  GanedenBC30 is also known as Bacillus coagulans GBI-30, PTA-6086.  Clinical trials show that GanedenBC30 is effective in irritable bowel syndrome (IBS), intestinal gas, rheumatoid arthritis, and in boosting the immune system against cold and flu viruses.  GanedenBC30 is currently being studied in IBS and depression by researchers at the Massachusetts General Hospital and in HIV infection by researchers at the AIDS Healthcare foundation.  For more information, visit www.Sustenex.com, www.DigestiveAdvantage.com, or www.GanedenLabs.com.


'/>"/>
SOURCE Ganeden Biotech
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
2. Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup
3. Grocery Manufacturers Association: Study Signals Progress in Battle Against Obesity
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
6. New Effort to Battle Antibiotic Resistance Rallies Researchers Throughout Harvard University
7. Hypoglycemia Education - A Vital Weapon in the Battle to Conquer Diabetes
8. A New Weapon In The Battle Of The Bra Bulge
9. Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries
10. While Ethicon Endo-Surgery and Allergan Remain Front-Runners in the $41 Million Gastric Band Market, Other Competitors Battle for Third Place, According to Millennium Research Group
11. ACLJ Gets Win for Pro-Life Pharmacy Owners in Illinois After Lengthy Legal Battle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  The University of ... announced today that, as part of the development ... of the first hospitals in the U.S. to start ... Muraszko , M.D., U-M,s chair of neurosurgery. ... neurosurgery. --> The BrightMatter technology from ...
(Date:2/8/2016)... CITY, Calif., Feb. 8, 2016  Aoxing Pharmaceutical Company, Inc. (NYSE ... fiscal year 2016, ended December 31, 2015, the Company achieved ... recorded in the same quarter in fiscal 2015. ... in Q2 of fiscal year 2016 was $2,068,635, or $.03 ... or $.01 per share, in the Q2 of fiscal year ...
(Date:2/8/2016)... Feb. 8, 2016 ... of the "Label-Free Detection Market by ... 2020" report to their offering. ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley Rubber ... Canada to provide its range of unique and advantaged protective solutions to ... that will provide bilingual customer service and marketing support. A new distribution center ...
(Date:2/8/2016)... (PRWEB) , ... February 08, ... ... and security executive networking and relationship-marketing firm, announced today that nominations will ... Information Security Executive® (ISE®) West Awards. , Awards include the Information ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from its ... 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than ... public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is ... this country. The AutismOne 2016 Conference, which is being held May 25-29 at the ... hear elsewhere about helpful interventions and causes of chronic illness in children. , Very ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd ... to his medical and surgical expertise. Technically known as deoxycholic acid or previously ... as a non-surgical alternative for reduction of fat below the chin (aka the ...
Breaking Medicine News(10 mins):